Compare Gilead Sciences, Inc. (GILD) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Gilead Sciences, Inc. trades at $150.85 (market cap $182.40B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $48.47 (market cap $73.20B). The key difference: Gilead Sciences, Inc. is far larger — about 2.5× Vanguard Sht-Term Inflation-Protected Sec Idx ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days on average.
| GILD | VTIP | |
|---|---|---|
Market Cap | $182.40B | $73.20B |
Volume | 4,469,821 | 2,511,360 |
Sector | Health | — |
52-Week High | $155.80 | $50.46 |
52-Week Low | $116.74 | $48.38 |
Typical Hold Time | 111 Days | 91 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
VTIP, the Vanguard Short-Term Inflation-Protected Securities ETF, trades at $48.475, up 0.03% on the day. Technical indicators show a bearish bias with moving averages signaling sell pressure, while oscillators like the 6-day relative strength index at 15.33 suggest oversold conditions. Recent news highlights its role as an inflation hedge amid rising energy prices and Fed rate hikes. The ETF focuses on short-duration TIPS to minimize interest rate risk, with institutional buying noted in recent SEC filings.
The outlook for VTIP is cautiously positive as a defensive inflation hedge, with real yields at multi-decade highs boosting appeal. However, risks include persistent inflation above the Fed's target and potential volatility from rate uncertainty. Investors seeking low-cost, short-duration inflation protection may find value, but the bearish technical trend warrants monitoring for stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
